175 related articles for article (PubMed ID: 31456235)
1. The Use of Biologics and Biosimilar in Asian patients with IBD: Are we ready?
Mak JW; Sung JJ
J Gastroenterol Hepatol; 2019 Aug; 34(8):1269-1270. PubMed ID: 31456235
[No Abstract] [Full Text] [Related]
2. Biosimilars for inflammatory bowel disease: how can healthcare professionals help address patients' concerns?
Gecse KB; Cumming F; D'Haens G
Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):143-155. PubMed ID: 30791783
[TBL] [Abstract][Full Text] [Related]
3. Insights on the use of biosimilars in the treatment of inflammatory bowel disease.
Zheng MK; Shih DQ; Chen GC
World J Gastroenterol; 2017 Mar; 23(11):1932-1943. PubMed ID: 28373759
[TBL] [Abstract][Full Text] [Related]
4. Potential Cost Implications of Mandatory Non-Medical Switching Policies for Biologics for Rheumatic Conditions and Inflammatory Bowel Disease in Canada.
Crosby M; Tadrous M; Gomes T
Clin Pharmacol Ther; 2021 Mar; 109(3):739-745. PubMed ID: 32909249
[TBL] [Abstract][Full Text] [Related]
5. ECCO position statement: the use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD).
Danese S; Gomollon F;
J Crohns Colitis; 2013 Aug; 7(7):586-9. PubMed ID: 23623738
[TBL] [Abstract][Full Text] [Related]
6. Forum discusses biosimilars, better biologicals.
Thompson CA
Am J Health Syst Pharm; 2011 Dec; 68(23):2210. PubMed ID: 22095804
[No Abstract] [Full Text] [Related]
7. Biosimilars versus biologics for inflammatory conditions.
Perry D; Ton J; Kolber MR
Can Fam Physician; 2019 Sep; 65(9):636. PubMed ID: 31515313
[No Abstract] [Full Text] [Related]
8. Advances in the use of biologics and other novel drugs for managing inflammatory bowel disease.
Park SH; Aniwan S; Loftus EV
Curr Opin Pharmacol; 2017 Dec; 37():65-71. PubMed ID: 28992449
[TBL] [Abstract][Full Text] [Related]
9. Biologicals and how they revolutionized rheumatology.
Grisar J
Wien Med Wochenschr; 2015 Jan; 165(1-2):1-2. PubMed ID: 25676698
[No Abstract] [Full Text] [Related]
10. Biosimilar Infliximab in Inflammatory Bowel Disease: Outcomes of a Managed Switching Programme.
Razanskaite V; Bettey M; Downey L; Wright J; Callaghan J; Rush M; Whiteoak S; Ker S; Perry K; Underhill C; Efrem E; Ahmed I; Cummings F
J Crohns Colitis; 2017 Jun; 11(6):690-696. PubMed ID: 28130330
[TBL] [Abstract][Full Text] [Related]
11. Positioning biologics-A case-based discussion: Anti-tumor necrosis factor biological agents/biosimilars.
Leong RW; Katelaris PH
J Gastroenterol Hepatol; 2018 Sep; 33 Suppl 3():14. PubMed ID: 30187561
[No Abstract] [Full Text] [Related]
12. Biosimilars and drug development in allergic and immunologic diseases.
Bonini S; Bonini M
J Allergy Clin Immunol; 2017 May; 139(5):1461-1464. PubMed ID: 28359671
[No Abstract] [Full Text] [Related]
13. Tracking the price of existing biologics when drugs enter the market.
Stiff KM; Cline A; Feldman SR
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):375-377. PubMed ID: 31177860
[No Abstract] [Full Text] [Related]
14. Biopharmaceuticals: Reference Products and Biosimilars to Treat Inflammatory Diseases.
Gils A; Bertolotto A; Mulleman D; Bejan-Angoulvant T; Declerck PJ
Ther Drug Monit; 2017 Aug; 39(4):308-315. PubMed ID: 28230618
[TBL] [Abstract][Full Text] [Related]
15. Identifying Key Benefits in European Off-Patent Biologics and Biosimilar Markets: It is Not Only About Price!
Dutta B; Huys I; Vulto AG; Simoens S
BioDrugs; 2020 Apr; 34(2):159-170. PubMed ID: 31792843
[TBL] [Abstract][Full Text] [Related]
16. Biosimilars in inflammatory bowel disease: ready for prime time?
Gomollón F
Curr Opin Gastroenterol; 2015 Jul; 31(4):290-5. PubMed ID: 26039720
[TBL] [Abstract][Full Text] [Related]
17. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
[TBL] [Abstract][Full Text] [Related]
18. [Biological and biosimilar drugs: Clarifying concepts].
Rodriguez Cumplido D; Asensio Ostos C
Aten Primaria; 2018; 50(6):323-324. PubMed ID: 29605234
[No Abstract] [Full Text] [Related]
19. Biosimilars in rheumatology: pharmacological and pharmacoeconomic issues.
Lapadula G; Ferraccioli GF
Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S102-6. PubMed ID: 23078880
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease.
Huoponen S; Eberl A; Räsänen P; Roine RP; Sipponen T; Arkkila P; Blom M
Medicine (Baltimore); 2020 Jan; 99(2):e18723. PubMed ID: 31914087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
